AI Article Synopsis
- Cardiac arrhythmias were common in a study of 20 patients on hemodialysis, with 90% showing ventricular arrhythmias (VAs), often correlating with the length of chronic renal failure (CRF).
- Sporadic VAs occurred in 75% of patients, and frequent VAs were found in 15%, while supraventricular arrhythmias (SVAs) were present in 80% of patients.
- The study found that VAs increased during hemodialysis and for four hours after, with no significant connections to other health metrics or demographics beyond CRF duration and use of acetate in dialysate.
Article Abstract
Cardiac arrhythmias were evaluated in 20 patients (14 males and 6 females; 38.2 +/- 17.6 years) undergoing regular maintenance hemodialysis (HD) for chronic and renal failure (CRF) by Holter ECG monitoring a 24-hour period. Ventricular arrhythmias (VAs) were observed in 18 of 20 patients (90%). Sporadic VAs were recorded in 75% and frequent VAs in 15% of 20 patients. It was found that VAs were correlated with an increase in duration of CRF, but there was no relation with age, duration of HD, frequency of HD, body surface area, the levels of serum sodium, chloride creatinine, phosphorous (P), magnesium, free calcium (Ca), and free fatty acids, Ca x P, cardiothoracic ratio, ejection fraction, fractional shortening, interventricular septum thickness, left ventricular wall thickness, left ventricular end-diastolic dimension and left ventricular end-diastolic index. VAs recorded frequently during HD and for 4 hours after HD. In addition, sporadic supraventricular arrhythmias (SVAs) were observed in 16 patients (80%) and frequent SVAs were recorded in 2 patients (10%). It was concluded that cardiac arrhythmias frequently developed in patients with CRF receiving HD, VAs significantly increase during HD and for 4 h after HD and frequency of VAs may be correlated with duration of CRF and the use of acetate as a buffer in the dialysate.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A PAS-targeting hERG1 activator reduces arrhythmic events in Jervell and Lange-Nielsen syndrome patient-derived hiPSC-CMs.
JCI Insight
January 2025
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, United States of America.
The hERG1 potassium channel conducts the cardiac repolarizing current, IKr. hERG1 has emerged as a therapeutic target for cardiac diseases marked by prolonged actional potential duration (APD). Unfortunately, many hERG1 activators display off-target and proarrhythmic effects that limit their therapeutic potential.
View Article and Find Full Text PDFAtrial Fibrillation and Retinal Stroke.
JAMA Netw Open
January 2025
Department of Neurology, Duke University School of Medicine, Durham, North Carolina.
Importance: Atrial fibrillation (AF) is the most common, chronic, cardiac arrythmia in older US adults. It is not known whether AF is independently associated with increased risk of retinal stroke (central retinal artery occlusion), a subtype of ischemic stroke that causes severely disabling visual loss in most cases and is a harbinger of further vascular events.
Objective: To determine whether there is an association between AF and retinal stroke.
Hot Phases Cardiomyopathy: Pathophysiology, Diagnostic Challenges, and Emerging Therapies.
Curr Cardiol Rep
January 2025
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), European Reference Network for Rare, University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy.
Purpose Of Review: Hot phases are a challenging clinical presentation in arrhythmogenic cardiomyopathy (ACM), marked by acute chest pain and elevated cardiac troponins in the absence of obstructive coronary disease. These episodes manifest as myocarditis and primarily affect young patients, contributing to a heightened risk of life-threatening arrhythmias and potential disease progression. This review aims to synthesize recent research on the pathophysiology, diagnostic challenges, and therapeutic management of hot phases in ACM.
View Article and Find Full Text PDFDesmoplakin Cardiomyopathy: Role of Inflammation and Potential Role of Disease-Modifying Therapies.
Curr Cardiol Rep
January 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.
Purpose Of Review: To summarize the available data on the use of immunosuppression therapies for the management of hot phases of disease and recurrent myocarditis in patients with desmoplakin cardiomyopathy (DSP-CMP).
Recent Findings: Occurrence of myocarditis episodes has been associated with worsening of outcomes in DSP-CMP. Multiple case reports and small case series have described potential benefit in using anti-inflammatory and immunosuppressive medications for the treatment of those episodes.
Objective: This study aimed to investigate the association between dapagliflozin and the incidence of atrial fibrillation (AF) and atrial flutter (AFL), along with its impact on all-cause mortality in patients with diabetes mellitus (DM).
Material And Methods: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this meta-analysis conducted a comprehensive search across PubMed, Embase, and ClinicalTrials.gov databases up to June 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!